Investigational Drug Information for Elesclomol
What is the drug development status for Elesclomol?
Elesclomol is an investigational drug.
There have been 5 clinical trials for Elesclomol.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Leukemia, Adenocarcinoma, and Carcinoma, Transitional Cell. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., National Cancer Institute (NCI), and GOG Foundation.
Summary for Elesclomol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 752 |
| WIPO Patent Applications | 227 |
| Japanese Patent Applications | 28 |
| Clinical Trial Progress | Phase 2 (2007-08-01) |
| Vendors | 62 |
Recent Clinical Trials for Elesclomol
| Title | Sponsor | Phase |
|---|---|---|
| Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Synta Pharmaceuticals Corp. | Phase 1 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | National Cancer Institute (NCI) | Phase 2 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | GOG Foundation | Phase 2 |
Clinical Trial Summary for Elesclomol
Top disease conditions for Elesclomol
Top clinical trial sponsors for Elesclomol
US Patents for Elesclomol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Elesclomol Development Update, Patent Position, and Market Projection
Elesclomol is an unapproved copper-binding mitochondrial drug candidate whose lead oncology program ended after a failed Phase III melanoma trial. Synta Pharmaceuticals discontinued development for metastatic melanoma in 2013 after the SYMMETRY study failed its overall-survival endpoint. No FDA-approved product, Orange Book listing, commercial revenue stream, or established generic market exists. Current commercial value depends on whether a sponsor can generate new clinical evidence in mitochondrial disease, neurodegeneration, or another non-oncology indication.
What is the current development status of elesclomol?
Elesclomol is not an approved drug and has no active late-stage commercial program disclosed in the public record.
The compound was developed primarily by Synta Pharmaceuticals as a mitochondrial-targeting copper ionophore. It forms a complex with copper and transports the metal into mitochondria, where excess copper can generate oxidative stress and impair mitochondrial function. The original development thesis focused on selectively stressing cancer cells with high oxidative and metabolic demands.
| Item | Status |
|---|---|
| Drug candidate | Elesclomol, commonly studied with paclitaxel |
| Lead developer | Synta Pharmaceuticals |
| Primary historical indication | Advanced metastatic melanoma |
| Mechanism | Copper ionophore and mitochondrial oxidative-stress modulator |
| Highest completed stage | Phase III |
| Lead Phase III study | SYMMETRY, NCT00529113 |
| Phase III result | Failed overall-survival endpoint |
| Oncology development | Discontinued |
| FDA approval | None |
| Orange Book listing | None identified |
| Current commercial sales | None |
| Biosimilar relevance | None; elesclomol is a small molecule, not a biologic |
The Phase III SYMMETRY trial compared elesclomol plus paclitaxel with paclitaxel alone in patients with advanced melanoma. The study was stopped after an interim analysis showed no meaningful overall-survival benefit. The final publication reported that the combination did not improve survival compared with paclitaxel alone (O'Rourke et al., 2013).
Why did the elesclomol melanoma program fail?
The oncology program failed because the randomized Phase III study did not confirm the efficacy signal observed in earlier-stage development.
Earlier studies suggested that elesclomol plus paclitaxel could produce disease control in advanced melanoma. The Phase III study enrolled a larger and more definitive population, but the treatment combination failed to improve overall survival. Development was then halted in the melanoma setting.
The failure creates several commercial constraints:
- The original clinical rationale was not validated in a registrational trial.
- Elesclomol was tested in an aggressive disease with rapidly changing treatment standards.
- The compound did not establish a clinically validated biomarker strategy.
- The development history may increase the evidence burden for any new indication.
- A future sponsor would need to distinguish a new mitochondrial-disease program from the failed oncology mechanism.
The failure does not establish that elesclomol lacks activity in all diseases. It does mean that historical melanoma data provide limited support for a future approval without new disease-specific evidence.
What indications are being considered for elesclomol?
The most plausible post-oncology opportunities are diseases involving mitochondrial dysfunction, copper metabolism, oxidative stress, or impaired cellular energy production.
Mitochondrial disease
Preclinical and translational research has continued to examine elesclomol and elesclomol-copper as potential mitochondrial modulators. The rationale is different from the oncology program. Instead of inducing lethal oxidative stress in cancer cells, researchers have investigated whether controlled copper delivery can improve mitochondrial respiration and energy production in cells with mitochondrial defects.
Potential target categories include:
- Primary mitochondrial disorders
- Friedreich ataxia
- Neurodegenerative diseases involving mitochondrial dysfunction
- Muscle diseases with impaired oxidative phosphorylation
- Rare metabolic disorders
These programs remain research-stage unless supported by a disclosed clinical trial, regulatory designation, or sponsor-led development program. A change in indication would require new safety, pharmacokinetic, dose-selection, and efficacy work.
Neurologic and neurodegenerative disease
Elesclomol has attracted research interest because mitochondrial dysfunction is implicated in several neurologic diseases. However, the commercial case is weaker than in oncology unless a sponsor can demonstrate:
- Target engagement in humans
- Reproducible mitochondrial biomarker improvement
- A clinically meaningful functional endpoint
- Acceptable chronic dosing
- A differentiated safety profile
The historical Phase III failure does not directly resolve those questions because melanoma treatment was short-term, combination-based, and directed at tumor control rather than restoration of mitochondrial function.
What patents protect elesclomol?
Elesclomol’s historical patent position is not equivalent to an active pharmaceutical exclusivity position.
Synta and predecessor research programs pursued patent protection around elesclomol compounds, analogues, metal complexes, pharmaceutical compositions, and therapeutic uses. The original composition-of-matter and broad compound claims are likely to face substantial age-related expiry pressure because the candidate entered clinical development in the 2000s.
| Patent category | Commercial relevance |
|---|---|
| Elesclomol composition claims | Potentially expired or approaching expiry, depending on family and patent-term adjustment |
| Copper-complex claims | May have different filing and expiry dates |
| Formulation claims | Could extend protection if technically narrow and enforceable |
| Method-of-use claims | May remain relevant for a new indication if filed later |
| Manufacturing claims | Could create process barriers without blocking independent synthesis |
| Diagnostic or biomarker claims | Potentially important for a precision-medicine program |
| Orange Book patents | None associated with an approved product |
No FDA-approved elesclomol product exists, so there is no current Orange Book patent listing for an elesclomol drug product. Patent-term analysis must distinguish between the original molecule, specific metal complexes, formulations, and newly developed indications. A historical patent family does not establish enforceable market exclusivity today.
Are there formulation patents for elesclomol?
Potential formulation protection could cover solubility enhancement, injectable delivery, stability, particle size, excipient systems, or a defined copper-to-drug ratio. Formulation claims would be commercially relevant only if a sponsor advances a product requiring a protected presentation.
The Phase III oncology program used intravenous administration with paclitaxel. A future mitochondrial-disease product could require a different dosing schedule or delivery system. Oral, subcutaneous, or chronic intravenous formulations would create separate technical and patent issues. No publicly established commercial formulation has achieved regulatory validation.
Are there method-of-use patents for elesclomol?
Method-of-use claims could cover treatment of a defined mitochondrial disorder, biomarker-selected patient population, or disease associated with copper deficiency or impaired oxidative phosphorylation. Such claims would be more relevant to future development than broad melanoma claims, provided the claims are supported by clinical data and survive validity challenges.
A new indication could qualify for regulatory exclusivity even if older compound patents have expired. Regulatory exclusivity, however, would depend on FDA approval and the applicable statutory pathway. Elesclomol currently has neither.
What is the FDA regulatory and Orange Book status of elesclomol?
Elesclomol has no FDA approval and no Orange Book listing.
The historical program advanced through clinical trials but did not produce a New Drug Application approval. As a result:
- There is no FDA-approved elesclomol label.
- There is no reference listed drug for an abbreviated new drug application.
- There is no current Paragraph IV pathway tied to an approved elesclomol product.
- There is no FDA-recognized product-specific exclusivity period.
- There is no established generic launch timetable.
- There is no biosimilar pathway because elesclomol is a small molecule.
A future sponsor would most likely need to submit a new investigational application and pursue a conventional 505(b)(1) development program unless a legally available reliance pathway were established. The failed oncology history may provide useful safety information, but it would not substitute for an indication-specific approval package.
When does elesclomol lose exclusivity?
Elesclomol has no active FDA product exclusivity because it has never been approved.
The relevant commercial question is whether any patent family can block development or sale of a new elesclomol product. That depends on:
- The earliest effective nonprovisional filing date
- Patent-term adjustment and terminal disclaimers
- Continuation and divisional claims
- Claims directed to copper complexes rather than the parent compound
- Formulation and manufacturing claims
- New method-of-use filings
- Patent ownership and assignment history
- Jurisdiction-specific validity and enforceability
The original development timeline indicates that early compound protection is unlikely to provide a long remaining exclusivity period in the United States. A later patent estate could still protect a specific formulation, indication, dosing regimen, or biomarker-defined population.
Are companies challenging elesclomol patents under Paragraph IV?
No active Paragraph IV challenge is associated with elesclomol because no approved elesclomol reference product is listed in the Orange Book.
Generic competition would arise only after an approved reference product exists. A future generic applicant could then file an abbreviated application and challenge listed patents, subject to the patent categories and exclusivity applicable at that time.
The more immediate competitive risk is not a conventional generic challenge. It is freedom to operate around old compound claims, new formulation patents, and any third-party patents covering mitochondrial-disease use or copper delivery.
What litigation and licensing deals affect elesclomol?
The principal commercial development record centers on Synta Pharmaceuticals’ clinical program and subsequent discontinuation of melanoma development. No active high-value licensing transaction or major patent settlement currently defines the asset’s market position.
The absence of an approved product also limits the likelihood of conventional generic litigation. Litigation risk would become material if:
- A new sponsor revives the program;
- The sponsor obtains approval for a rare mitochondrial disease;
- New formulation or method-of-use patents are listed;
- A competitor develops an alternative copper-ionophore therapy;
- A licensee seeks to commercialize a protected product in multiple jurisdictions.
A transaction involving elesclomol would likely be structured around rights to a defined indication, patent families, clinical data, or a new formulation rather than around established product revenue.
How strong is the elesclomol patent estate?
The patent estate appears strategically weak for broad market exclusivity but potentially useful for a redesigned development program.
| Patent-estate factor | Assessment |
|---|---|
| Original compound protection | Likely aged and subject to expiry pressure |
| FDA regulatory exclusivity | None |
| Orange Book leverage | None |
| Clinical validation | Weak after Phase III melanoma failure |
| New indication opportunity | Possible, but unvalidated |
| Formulation opportunity | Potentially meaningful if a new presentation is required |
| Manufacturing barriers | Possible, but unlikely to block all independent synthesis |
| Biomarker protection | Potentially important in a revived program |
| Litigation leverage | Limited without an approved product |
| Licensing attractiveness | Dependent on new clinical data |
A sponsor could improve the effective protection period by developing a differentiated formulation, identifying a biomarker-selected population, or pursuing a rare disease with orphan-drug exclusivity. Those strategies would require new data and would not restore expired broad compound claims.
What is the market projection for elesclomol?
The base-case commercial projection is zero near-term revenue because elesclomol has no approved indication, no active commercial supply chain, and no established reimbursement market.
Scenario-based market outlook
| Scenario | Probability profile | Commercial outcome |
|---|---|---|
| Base case | No sponsor restarts clinical development | No product revenue through the medium term |
| Research continuation | Academic or translational studies continue | No material market |
| Orphan-disease revival | Sponsor produces clinical proof in mitochondrial disease | Small, premium-priced specialty market |
| Broad neurologic expansion | Positive evidence across larger populations | Larger opportunity, but high clinical and regulatory risk |
| Oncology revival | New biomarker-defined efficacy emerges | Low probability given prior Phase III failure |
If revived for a rare mitochondrial disease, the addressable population would likely be small, but annual treatment prices could be high. A commercial product would face substantial costs for diagnosis, specialist-center distribution, patient identification, long-term safety monitoring, and reimbursement evidence.
A reasonable investment framework is:
- Near-term revenue exposure: $0
- Current approved-product value: $0
- Development-option value: dependent on sponsor commitment and new clinical data
- Generic-entry exposure: none today
- Upside driver: successful proof of concept in a mitochondrial indication
- Principal downside: failure to reproduce biological benefit in humans
No credible market forecast should treat historical melanoma sales assumptions as a current revenue base.
How does elesclomol compare with competing mitochondrial drug candidates?
Elesclomol competes indirectly with therapies targeting mitochondrial energy failure, oxidative stress, iron metabolism, and rare metabolic disease. Its differentiation is the copper-ionophore mechanism rather than a conventional antioxidant or substrate-replacement approach.
| Attribute | Elesclomol | Established mitochondrial therapies |
|---|---|---|
| Approval status | Unapproved | Varies by product and indication |
| Mechanism | Copper delivery and mitochondrial modulation | Disease-specific or pathway-specific |
| Clinical evidence | Failed Phase III in melanoma | Depends on indication |
| Commercial infrastructure | None | Existing for approved products |
| Patent position | Aged historical estate; new-use potential | Varies |
| Development risk | High | Lower for approved comparators |
| Best market fit | Rare mitochondrial disease if validated | Existing labeled diseases and specialty indications |
The principal disadvantage is the absence of validated clinical efficacy in the proposed non-oncology indications. The potential advantage is a mechanism that could address mitochondrial dysfunction upstream of some disease manifestations.
What generic launch risks exist for elesclomol?
There is no immediate generic launch risk because no reference product is approved.
If elesclomol receives approval in the future, generic risk would depend on the product’s patent architecture:
- Broad composition claims would offer the strongest protection if still enforceable.
- Formulation claims could delay substitution but may be easier to design around.
- Method-of-use claims may have limited value where labels can be carved out.
- Manufacturing claims could raise costs without preventing all competitors.
- Orphan-drug exclusivity could provide separate regulatory protection.
- A rare-disease label may limit the commercial attractiveness of generic entry.
The greatest future risk may come from alternative mitochondrial therapies rather than immediate generic substitution.
What geographic markets could support elesclomol?
The United States would likely be the primary development and commercial jurisdiction because of its rare-disease regulatory framework, specialty reimbursement system, and established mitochondrial-disease centers.
Europe and Japan could become relevant if a sponsor demonstrates efficacy in a genetically defined disorder. Geographic patent protection would need to be reviewed separately across:
- United States
- European Patent Convention states
- Japan
- China
- Canada
- Australia
An old international patent filing does not guarantee current enforceability in every country. Maintenance fees, national-phase entry, patent expiration, claim scope, and ownership must be assessed jurisdiction by jurisdiction.
Key Takeaways
- Elesclomol is an unapproved copper-ionophore drug candidate.
- Its Phase III melanoma program failed and was discontinued in 2013.
- No FDA approval, Orange Book listing, Paragraph IV challenge, or commercial revenue exists.
- The strongest potential repositioning opportunity is mitochondrial disease, but clinical validation remains absent.
- Original compound patents are likely subject to substantial age and expiry pressure.
- New formulation, biomarker, manufacturing, or method-of-use patents could create a narrower future protection strategy.
- The current market projection is zero near-term revenue.
- Commercial upside depends on a new sponsor, a validated indication, and regulatory evidence that separates the asset from its failed oncology history.
FAQs
Is elesclomol still being developed for cancer?
No active late-stage cancer program is established. The lead melanoma program ended after the Phase III SYMMETRY trial failed to improve overall survival.
Is elesclomol approved for Friedreich ataxia?
No. Elesclomol is not FDA-approved for Friedreich ataxia or any other disease.
Is elesclomol a copper supplement?
No. Elesclomol is a synthetic copper-binding compound designed to transport copper into cells and mitochondria. Its pharmacology differs from nutritional copper supplementation.
Can a generic company launch elesclomol now?
No approved reference product exists, so a conventional abbreviated generic launch cannot occur today.
What would make elesclomol commercially valuable again?
Human proof of benefit in a defined mitochondrial disease, a tolerable chronic dosing regimen, and a defensible formulation or indication-specific patent strategy would be required to create material commercial value.
References
-
ClinicalTrials.gov. (n.d.). NCT00529113: A study of elesclomol sodium in combination with paclitaxel in patients with advanced melanoma. U.S. National Library of Medicine.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
O'Rourke, M. G., et al. (2013). A randomized placebo-controlled phase III study of elesclomol plus paclitaxel versus paclitaxel alone in patients with advanced melanoma. Journal of Clinical Oncology.
-
Synta Pharmaceuticals Corp. (2014). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
-
National Cancer Institute. (n.d.). Elesclomol. NCI Drug Dictionary.
More… ↓
